Lilly drops three clinical programs, including a gene therapy from Prevail
Three experimental treatments, none of them GLP-1 drugs, are off Lilly's pipeline as the company concentrates spending on cardiometabolic and immunology medicines.
Eli Lilly has discontinued three clinical-stage programs, including a gene therapy for a rare inherited form of dementia that came out of its $1 billion-plus purchase of Prevail Therapeutics, the company disclosed on Feb. 4, 2026 [1].
The gene therapy, LY3884963 — formerly known as PR006 — was being tested in a phase 1/2 trial for frontotemporal dementia linked to changes in the progranulin (GRN) gene, a condition that is primarily inherited and can lead to changes in behavior and executive functioning [1]. The trial started in 2020, included five treatment cohorts across different doses, dosing methods and disease stages, and had a primary readout listed on ClinicalTrials.gov for 2031 [1].
A Lilly spokesperson said the company "discontinued GRN gene therapy in frontotemporal dementia due to a lack of compelling efficacy in the studied patient population. The decision was not due to any safety concern" [1]. Patients already enrolled will take part in a safety follow-up period, and the company said it plans to share data at a forthcoming scientific meeting, without giving a date [1].
The second cut is LY3541860, an anti-CD19 antibody tested in mid-stage studies for both multiple sclerosis and rheumatoid arthritis [1]. In the rheumatoid arthritis trial, the drug was evaluated in 35 patients, with a phase 2a primary readout scheduled for November of last year [1]. The multiple sclerosis phase 2a/2b trial was expected to enroll 200 patients over four years, was most recently listed as "recruiting," and had a readout listed for August 2027 [1]. Lilly said the termination "was not safety-driven" and that the asset "did not meet Lilly's high bar for continued development" [1].
The third, AC-225-PSMA-62, is an investigational radioligand therapy that was in a phase 1/2 trial for prostate-specific membrane antigen (PSMA)-positive prostate cancer with limited spread, with a primary readout scheduled for September 2027 [1]. According to the spokesperson, it did not meet Lilly's "bar for differentiated efficacy to advance to phase 2," and the termination was not related to "any new or unexpected safety findings" [1].
The disclosures came alongside Lilly's earnings report. In the most recent quarter, Lilly's research and development spending rose 26% to $3.8 billion, or 20% of revenue [1]. The company is awaiting an FDA approval decision for orforglipron, its oral GLP-1, and has secured a Commissioner's National Priority Voucher that could accelerate that decision [1].
Lilly is continuing other gene therapy work, including a mid-stage GBA1 gene therapy that Prevail had described as its lead asset, studied in Parkinson's disease and Gaucher disease type 1 [1]. The company also recently signed a deal potentially worth more than $1 billion with Germany's Seamless Therapeutics for a genetic medicine for hearing loss [1]. Asked whether the pipeline cuts involved layoffs, a spokesperson said, "There are no large-scale workforce reductions underway at Lilly" [1].
Why it matters for patients
People with FTD-GRN frontotemporal dementia, multiple sclerosis, rheumatoid arthritis or this type of prostate cancer lose access to an experimental treatment option. These programs were in human trials, so the effect falls on participants and on patients who might have enrolled later, not on anyone taking an approved medicine. Nothing in the disclosures changes the status of Lilly's marketed GLP-1 and diabetes drugs or of tirzepatide; the discontinued products are not GLP-1 or tirzepatide medicines [1].
For people already taking a GLP-1, the practical signal here is about where Lilly is putting its research money. The company said the cuts reflect a decision to concentrate resources on cardiometabolic and immunology [1], and its research budget grew in the latest quarter [1]. It has not been reported whether trial participants outside the gene therapy study will receive continued access to the discontinued treatments, or what that access would look like.
What happens next
Patients who received the GRN gene therapy will continue in a safety follow-up period, and Lilly says it plans to present the program's data at a scientific meeting; no date has been disclosed [1].
ClinicalTrials.gov had listed an August 2027 readout for the multiple sclerosis trial and a September 2027 readout for the prostate cancer radioligand trial [1]. Whether those readouts will still take place has not been disclosed.
Lilly has not announced a date for the FDA decision on orforglipron, saying only that a national priority voucher could speed it up [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.